La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Harbin Pharmaceutical Group Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Harbin Pharmaceutical Group.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	18.8%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

Jun 25

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

May 25

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Apr 17

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Harbin Pharmaceutical Group n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SHSE:600664 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2024	15,667	450	411	496	N/A
12/31/2023	15,457	395	863	950	N/A
9/30/2023	15,398	598	1,138	1,219	N/A
6/30/2023	15,096	526	925	988	N/A
3/31/2023	14,406	487	576	650	N/A
12/31/2022	13,809	465	532	622	N/A
9/30/2022	13,053	41	34	137	N/A
6/30/2022	12,812	151	-252	-157	N/A
3/31/2022	13,156	389	73	166	N/A
12/31/2021	12,802	371	-239	-162	N/A
9/30/2021	12,879	-219	-903	-811	N/A
6/30/2021	12,385	-402	-511	-402	N/A
3/31/2021	11,258	-808	-1,015	-902	N/A
12/31/2020	10,788	-1,078	-846	-728	N/A
9/30/2020	11,009	-321	-289	-209	N/A
6/30/2020	11,118	-235	-334	-271	N/A
3/31/2020	11,661	14	-162	-107	N/A
12/31/2019	11,825	56	-324	-285	N/A
9/30/2019	11,174	107	293	390	N/A
6/30/2019	10,696	-59	318	418	N/A
3/31/2019	10,630	61	262	372	N/A
12/31/2018	10,814	346	579	693	N/A
9/30/2018	10,910	386	111	197	N/A
6/30/2018	11,484	422	-137	-36	N/A
3/31/2018	11,790	501	102	202	N/A
12/31/2017	12,018	407	N/A	149	N/A
9/30/2017	12,993	441	N/A	598	N/A
6/30/2017	13,180	757	N/A	1,110	N/A
3/31/2017	13,761	737	N/A	1,833	N/A
12/31/2016	14,127	788	N/A	2,778	N/A
9/30/2016	13,662	789	N/A	3,179	N/A
6/30/2016	13,830	584	N/A	3,553	N/A
3/31/2016	14,435	515	N/A	2,929	N/A
12/31/2015	15,856	580	N/A	1,660	N/A
9/30/2015	16,038	324	N/A	899	N/A
6/30/2015	16,622	302	N/A	498	N/A
3/31/2015	16,290	238	N/A	945	N/A
12/31/2014	16,509	247	N/A	1,136	N/A
9/30/2014	17,382	230	N/A	715	N/A
6/30/2014	18,019	307	N/A	142	N/A
3/31/2014	18,402	107	N/A	-9	N/A
12/31/2013	18,092	169	N/A	142	N/A
9/30/2013	17,903	476	N/A	365	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if 600664's forecast earnings growth is above the savings rate (2.9%).

Bénéfices vs marché: Insufficient data to determine if 600664's earnings are forecast to grow faster than the CN market

Croissance élevée des bénéfices: Insufficient data to determine if 600664's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if 600664's revenue is forecast to grow faster than the CN market.

Croissance élevée des revenus: Insufficient data to determine if 600664's revenue is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if 600664's Return on Equity is forecast to be high in 3 years time

Harbin Pharmaceutical Group Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

High number of new and inexperienced directors

Investor sentiment improves as stock rises 18%

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.05 in 1Q 2023)

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 18%

Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024

Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)

Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)

Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) dropped from S&P Global BMI Index

New 90-day low: CN¥2.84

New 90-day low: CN¥3.09

New 90-day low: CN¥3.22

Third quarter earnings released

New 90-day low: CN¥3.33

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance